Procter & Gamble Health announces Fourth Quarter and Fiscal Year Results

Procter & Gamble Health Limited today announced its financial results for the quarter and fiscal year ended 30th June, 2023. The fourth quarter reported a sale of ₹ 306.6 crores up by about 3% versus same quarter previous year. The sales grew at low single digit against the headwinds of slowing down of the category in the quarter. The company reported a PAT of ₹29.8 Crore a decline of 28% against the previous year on account of higher material cost and one-time employee cost.

The company has recorded a strong performance with sales of ₹1206 crores, up by 10% vs previous year, for the year ending 30th June, 2023. Profit After Tax (PAT) for the year ended 30th June 2023 is ₹ 229 crores, up by 19% versus previous fiscal year.

"We continued our efforts towards brand and category development and thus delivered a strong performance in the fiscal, marked by consistent growth across all our brands. The quarter, however, witnessed a category slowdown across our portfolio. Despite these challenges, we continued our commitment to our strategy of five integrated choices: a portfolio of daily-use products where performance drives brand choice; superiority across product, package, brand communication, retail execution, and value; productivity; constructive disruption of the entire value chain; and a highly efficient and effective organization structure.

We raised awareness and education among our consumers through initiatives like the Neuropathy Awareness Week, wherein leading Global Health Experts converged to address the growing Public Health Concern of Peripheral Neuropathy. This also reinforced our efforts towards building an ecosystem for scientific collaboration and knowledge-sharing among healthcare professionals.

We also commemorated World Health Day by launching the Pragati Utsav, an initiative to raise awareness and empower the healthcare professionals of rural hinterlands, on Vitamin B deficiency. We bolstered our go-to-market strategy and strengthened our partnerships across omni channel stores, increasing the availability and access of our brands across online and offline platforms, thereby helping meet the needs of our consumers and customers.

We launched the first-of-its-kind policies for employees, including the end-to-end support for children with special needs and a co pay India Day Care policy, we continued to foster an environment of equal opportunities at the workplace. SEHAT, our flagship CSR program, continued to remain a priority during this fiscal year where we continued to strengthen public health through our strategic initiatives," said Milind Thatte, Managing Director, Procter & Gamble Health Limited.

The Board of Directors have recommended a final dividend of ₹ 50 per Equity Share, for the Financial Year ending June 30, 2023. Considering interim dividend of ₹ 45 per share, total dividend payout for the fiscal will be ₹ 95 per share, subject to the approval of final dividend by shareholders of the company at the ensuing 56th Annual General Meeting.

Shares of Procter & Gamble Health Limited was last trading in BSE at Rs. 5333.80 as compared to the previous close of Rs. 5360.10. The total number of shares traded during the day was 529 in over 252 trades.

The stock hit an intraday high of Rs. 5396.70 and intraday low of 5294.15. The net turnover during the day was Rs. 2829745.00.

Source : Equity Bulls

Keywords

ProcterandGambleHealth INE199A01012 Q4FY23 FY2023 ResultUpdate